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We performed a prospective genotype-phenotype study using molecular screening and 
clinical assessment to compare the severity of disease and the risk of sarcoma in 172 
individuals (78 families) with hereditary multiple exostoses. We calculated the severity of 
disease including stature, number of exostoses, number of surgical procedures that were 
necessary, deformity and functional parameters and used molecular techniques to identify 
the genetic mutations in affected individuals. Each arm of the genotype-phenotype study 
was blind to the outcome of the other. Mutations EXT1 and EXT2 were almost equally 
common, and were identified in 83% of individuals. Non-parametric statistical tests 
were used.
There was a wide variation in the severity of disease. Children under ten years of age had 
fewer exostoses, consistent with the known age-related penetrance of this condition. The 
severity of the disease did not differ significantly with gender and was very variable within 
any given family. The sites of mutation affected the severity of disease with patients with 
EXT1 mutations having a significantly worse condition than those with EXT2 mutations in 
three of five parameters of severity (stature, deformity and functional parameters). A single 
sarcoma developed in an EXT2 mutation carrier, compared with seven in EXT1 mutation 
carriers. There was no evidence that sarcomas arose more commonly in families in whom 
the disease was more severe.
The sarcoma risk in EXT1 carriers is similar to the risk of breast cancer in an older 
population subjected to breast-screening, suggesting that a role for regular screening in 
patients with hereditary multiple exostoses is justifiable.
Hereditary multiple exostoses (HME), also
known as multiple hereditary exostoses, multi-
ple osteochondromatosis or diaphyseal aclasis,
is an autosomal dominant inherited trait with
an incidence of at least one in 50 000, which
makes it one of the most common inherited
musculoskeletal conditions.1 Multiple carti-
lage capped exostoses develop during child-
hood and adolescence in the metaphyseal
region of long bones, resulting in short stature
and deformity, often requiring corrective sur-
gery.1,2 Most lesions stagnate and ossify when
skeletal growth is complete, but occasionally
one might grow more aggressively or reactivate
as a chondrosarcoma.3-5 The severity of dis-
ease in HME varies considerably. Some indi-
viduals achieve normal height with few
exostoses, whereas others are badly affected.
Radiological studies confirm this variation, yet
the factors that determine severity of the dis-
ease are not known.1,2
It is possible that some, or all, of the varia-
tion is due to genetic differences. In conditions
such as achondroplasia, a single gene is
affected in the same way in all patients. In
patients with HME, two different genes, each
on different chromosomes, are associated with
the condition. It has also been shown that a
variety of mutations occur in these genes in
HME. It has been suggested that genetic varia-
tion could account for the difference in severity
of the disease.6-11 Knudson12 demonstrated a
mathematical relationship between observed
numbers of tumours and cellular mutation
rates in familial neoplastic traits. The risk of
malignant change might also be related to
osteochondroma load and severity of the dis-
ease. Therefore, we designed a prospective
study to assess the risk of sarcoma formation
and the variation in  severity with different
genetic mutations, to determine whether a par-
ticular mutation had a morbid effect.
Patients and Methods
Our prospective study comprised 172 individ-
uals (78 families) with HME. The researchers
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collecting the genotype data were ‘blind’ to the results of
the phenotype data,  and vice versa. Index patients with
solitary osteochondromas were excluded.
The phenotype can be characterised in several ways.
Most relevant to disease activity is the number of exostoses,
especially as genetic epidemiology predicts this to be a
major determinant of the risk of sarcoma.12,13 Assessing the
number of osteochondromas by clinical examination alone
has previously been shown to correlate with radiological
data,2 suggesting that in population studies, clinical exam-
ination provides a reliable estimate of the severity of disease
and avoids the theoretical risk of malignant change associ-
ated with  ionising radiation.14,15
Population-based studies have defined some deformities
which are inherent in HME. These include short ulnae, dis-
located proximal radio-ulnar joint, forearm bowing, genu
vara/valga and short stature generally.1 Handicap, however,
is reflected in functional parameters, as well as anatomical
ones. It is recognised that some osteochondromas have
greater disabling effects than others (such as those close to
the distal ulnar epiphysis) and an assessment of the disease
phenotype has to take this into account.2 Disability (func-
tional effects) include reduced range of movement of elbow,
forearm and knee. The severity of these deforming and
functional features of HME are graded in Table I. Standing
height was measured and compared with age and gender-
matched data from Buckler-Tanner.16 The number of exo-
stoses, the number of previous surgical operations and
the magnitude of the deforming and functional effect of
osteochondroma were compared in separate genotype-
phenotype analyses.
Patients were selected by referral from orthopaedic sur-
geons, geneticists and occasionally they presented them-
selves, between 1996 and 2000. All had the clinical
manifestations of HME.
All patients were informed of the programme and agreed
to take part. Ethical approval was obtained for sample col-
lection and analysis. A clinical history was obtained and a
family pedigree. The clinical data was collected by clinical
examination carried out by a single examiner (MF) who
was blind to all genotypic data.
Genomic DNA was extracted either from blood, using
the Nucleon DNA extraction Kit (Scotlab, Lanarkshire,
UK), or from buccal swabs by a previously described pro-
tocol.10 The lab investigator was blind to phenotypic data.
The initial mutational analysis of EXT1 and EXT2 was
carried out by conformation-sensitive gel electrophoresis
and fluorescent single-strand conformation polymorphism
analysis, but the greater part of the study was carried out
using denaturing high-performance liquid chromatography
(DHPLC).10,11 EXT1 and EXT2 exons and their flanking
intronic regions were amplified by polymerase chain re-
action (PCR) from genomic DNA isolated from proband
samples by the use of specific primer pairs. For DHPLC
analysis the initial primer pairs used were as previously
ment Analysis System (Transgenomic, Cheshire, UK).11 The
full sequence of the PCR product for all fragments were
entered into the Transgenomic WAVEMaker 3.4 program
(Transgenomic). This enabled the temperature and gradient
conditions for each fragment to be selected. The crude PCR
products, which had been denatured, followed by gradual
re-annealing, were injected into a DNASep column (Trans-
genomic). The column mobile phase consisted of a linear
acetonitrile gradient in a 0.1 M triethylamine acetate buffer
(TEAA). The calculated gradient, at a flow rate of 0.9 ml/
min, was run for all the amplicons at the relevant column
temperature for each fragment.
Where a variant chromatograph was obtained, the frag-
ment was amplified by PCR using the same primers and the
DNA sequence determined. The PCR product was purified
through a spin column, using a QIAquick PCR purification
kit (Qiagen, Crowley, UK), then sequenced in both direc-
tions using BigDye Terminator Cycle Sequencing Ready
Reaction kit (PE-Applied Biosystems, Warrington, UK) and
run on an ABI 377 DNA Sequencer (PE-Applied Biosys-
tems). DNA from both affected and unaffected family
members was sequenced.
Table I. Severity scoring criteria for deformity and functional scores in
HME disease
Criterion Severity Score
Deformity
Ulnar length as a proportion of 
height (%)
>14 0
13 to13.9 1
12 to12.9 2
<12 3
Forearm deformity None 0
Ulnar negative variance 
without bowing
1
Forearm bowing (no 
radial head dislocation)
2
Radial head dislocation 3
Knee deformity (˚) None 0
Genu vaga 5 to10 1
Genu vaga 10 to15 2
Genu vaga >15 3
Range 0 to 18 
(bilateral 
assessment)
Functional
Forearm range of rotation (˚) >180 0
160 to 179 1
140 to 159 2
<140 3
Elbow range of flexion (˚) >140 0
130 to 139 1
120 to 129 2
<120 3
Knee range of flexion (˚) >130 0
120 to 129 1
110 to 119 2
<110 3
Range 0 to 18 
(bilateral 
assessment)
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Statistical analysis. Individuals from the same family cannot
be viewed as truly independent of each other. Therefore,
except for analyses of age and gender, all analyses were
undertaken on the mean value of the numbers of exostoses,
deformity and functional grading, in each family. No
matter how many family members were assessed, only one
datum point was generated for each family. Statistical anal-
ysis of all data was undertaken using non-parametric tests
(chi-squared, Wilcoxon rank-sum test, and Kendall’s test of
rank correlation).
Results
Between 1996 and 2000, we assessed the genotype and
phenotype of 172 individuals from 78 families with HME.
Genotyping revealed 71 individuals (34 families) with
EXT1 mutation, 72 (27 families) with EXT2 and 29 (17
families) with no identifiable mutation. The majority (50 of
61 families with known mutations) were loss-of-function
mutations.
The number of palpable exostoses varied considerably
from site to site. Their anatomical frequency in our series is
recorded in Figure 1. Age-distribution is shown in Figure 2.
The number of exostoses in individuals ranged from zero to
172, but did not demonstrate a significant correlation with
age (rank correlation coefficient = 0.027, p = 0.296). A
trend towards fewer exostoses, however, was seen in chil-
dren up to the age of ten years (Fig. 2) who were almost
equally represented in both EXT1 (n = 18) and EXT2
(n = 16) mutation groups.
There were 82 men and boys and 90 women and girls.
There was a trend towards more severe disease in the men
and boys than in the women and girls, but this failed to
reach statistical significance in the several parameters of
severity which were assessed (median number of exostoses
27 and 22, respectively; z = 1.840, p = 0.066). Boys and
girls were almost equally represented in the group aged less
than ten years. Gender was not significantly different
between families with EXT1 and EXT2 mutations.
Definite loss-of-function mutations were found in 50
families and missense mutations in 11. In 17 families no
mutation could be identified. When the numbers of exo-
stoses were compared in families with loss-of-function and
missense mutations, no significant difference was noted
(median number of exostoses 29 and 24, respectively;
z = 0.993, p = 0.321). Of 14 new unpublished mutations in
our data-set, 13 were loss-of-function and one a missense
mutation.
Families with an EXT1 mutation had significantly worse
disease than those with an EXT2 mutation across several
parameters of severity (Fig. 3); 19 of 34 families (56%)
with EXT1 consisted of individuals whose mean height was
below the 25th centile, compared with six of 27 individuals
(22%) in families with EXT2 (X2 = 7.050, p = 0.008). The
median family height in families with the EXT1 mutation
was on the 18th centile, and that for families with the EXT2
mutation was on the 50th centile. Individual deformity
scores ranged from zero to 17 from a total of 18. Signifi-
cantly greater deformity scores were recorded in families
with the EXT1 mutation than those with EXT2 (median
score 5.0 and 1.8, respectively; z = 3.532, p = 0.0004). Indi-
vidual functional scores ranged from zero to 16 from a total
of 18. Significantly worse functional scores were recorded
in families with the EXT1 mutation than those with EXT2
(median score 6.0 and 3.1, respectively; z = 2.512,
p = 0.012).
The number of exostoses per individual varied between
zero and 172. The number of exostoses were similar in
Clavicle 3.7%
Distal humerus 0.4%
Scapula 3.4%
Ribs 4.2%
Spine 0.1%
Proximal humerus 6.9%
Pelvis 2.1%
Proximal radius 1.0%
Proximal ulna 0.2%
Distal radius 9.7%
Distal ulna 5.5%
Proximal tibia 8.4%
Proximal fibula 6.2%
Distal tibia 8.3%
Distal fibula 6.9%
Hand 17.3%Proximal femur 0.2%
Distal femur 10.9%
Foot 4.6%
Fig. 1
Percentage of palpable exostoses found in the 172 individuals with HME
by anatomical site.
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families with EXT1 and EXT2 mutations (median 27 and
29, mean 37 and 29, respectively; z = 1.430, p = 0.153).
A total of ten chondrosarcomas occurred in nine fami-
lies; seven in subjects within the study and three in relatives
who had already died (Table II). All sarcoma patients inher-
ited loss-of-function mutations in their defective EXT gene;
seven sarcomas occured in EXT1 mutation carriers, and
only one in an EXT2 mutation carrier. No statistical differ-
ence was identified when the number of exostoses was com-
pared in families with or without a family history of
sarcoma (median of exostoses 37 and 28, respectively; z =
0.962, p = 0.336).
Discussion
Both epidemiological and clinical features of this condition
allow its classification as a familial (mostly benign) neoplas-
tic trait.2,13 This assertion is strengthened by molecular
genetic evidence which strongly suggests a clonal aetiology
Table II. Profile of chondrosarcomas in individuals affected with HME
EXT1 
mutation
EXT2 
mutation
No mutation 
identified Site
Sarcoma in examined individual 6 0 1 2 x scapula, 2 x spine, pelvis, 
rib, proximal humerus
Sarcoma reported in relative 1 1 1 2 x pelvis, femur
Total 7 1 2
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Fig. 2
Number of exostoses by age demonstrating age-
dependent phenotypic penetrance up to the age of ten
years.
Fig. 3
Parameters of disease severity of HME in families with
EXT1 and EXT2 mutations.
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for the osteochondroma and that a ‘two-hit’ model for
HME pathogenesis is appropriate. Mutations of the germ
line in the EXT tumour suppressor gene family have been
identified in HME.6-10,12,17-22 The risk of sarcoma in HME
is estimated, in population-based series, to be smaller than
initially thought. Recent estimates would suggest a lifetime
risk of about 2% to 4%.3,23-25 In published series, the
EXT1 mutation has been identified in about 45% of HME
patients and about 40% in the EXT2. The remaining 15%
have no identified mutation of the germ line.6-11 In our
group, the ratio of families with EXT1 and EXT2 muta-
tions is similar to those in other published series, both self-
selected and hospital-based.8,10,11 The anatomical distribu-
tion is also similar to published radiological skeletal sur-
veys, although the numbers identified close to deep-seated
joints (proximal femur, pelvis) are lower.1,5,25,26
Our results confirm an age-related phenotypic pene-
trance. This is widely acknowledged in HME and consist-
ent with published data, which report an age-dependent
disease penetrance and a median age of first diagnosis of
HME5 of three years.1 A trend towards worse disease was
observed in men and boys. These results are consistent with
other studies and suggest only a limited role for the disease-
modifying effects of gender.1,5
Although loss-of-function mutations result in no useful
gene-product, missense mutations (substitution of one
amino acid for another) might allow partial gene-function
if the mutation did not occur at a critical site. Our data
reveal that the majority of EXT mutations are associated
with loss-of-function, which would be expected in a
tumour-suppressor gene, requiring knock-out for disease-
expression. Furthermore, most missense mutations (10 of
11) have been previously described,27 suggesting that they
occur in crucial sites causing an effective ‘knock-out’ of the
gene. Consequently, similar disease severities might be
expected.
The findings of an earlier smaller genotype-phenotype
study in HME concur with our results.28 Our group of
patients is considerably larger, enabling the variables of age
and gender to be examined. EXT1 mutation is found more
frequently than EXT2 mutation in solitary exostoses, but it
is not yet known why this gene has a more dominant role in
severity of disease and sarcoma-risk in HME.22 It is likely
that a large non-EXT gene component to severity of disease
exists since family members frequently exhibit a wide range
of HME scores (Fig. 4).
In regard to the association between the EXT1 mutation
and chondrosarcoma, three questions arise; is it worth
screening for pre-malignant disease, and if so, how and in
whom? Given a lifetime risk of approximately 3%, most of
which occurs in the third to fifth decades of life, it would
seem reasonable to assess the annual risk of sarcoma in this
age group to be 0.1%.3,22-24 Possibly this risk might be dou-
bled in EXT1 mutation carriers. By comparison, the inci-
dence of breast cancer is 0.2% per annum between the ages
of 50 and 60 years;29 an age group in which mammo-
graphic screening is recommended in many countries. By
this comparison, a screening programme in HME (in
particular EXT1 mutation carriers) might seem to be
appropriate.
Current practice is in favour of clinical examination once
every year or two. There are no data on the number of
malignancies that develop between screening visits, nor on
the efficacy of such a programme. In our series only 13.5%
of palpable exostoses were found in the axial skeleton (Fig.
1), while in a large recent report of chondrosarcomas in
HME, 80% of tumours occurred in the axial skeleton.30
Worries, therefore, exist as to whether deep-seated axial
exostoses or chondrosarcomas can be identified by clinical
examination alone. Radiological surveys deliver a signifi-
cant radiation dose, and have theoretical risks in a condi-
tion now identified as a familial neoplastic trait. Magnetic
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Fig. 4
Number of exostoses (mean and range) for each fam-
ily with HME.
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resonance imaging of the axial skeleton is a promising line
of investigation in screening and positron-emission tomog-
raphy has also been used to study exostosis activity. Both
imaging modalities may have a role in screening, however,
no published data on their efficacy exist.
Given that families with a history of sarcoma do not have
a significantly greater median HME score than those with
no such history, it seems that severity of disease alone
cannot be utilised as a marker of the risk of malignant
change. EXT gene testing may have a role, but at least one
sarcoma has been reported in an EXT2 mutation carrier,21
in addition to the patient reported here. Thus, all known
patients with HME may benefit from inclusion in a screen-
ing programme.
The Arthritis Research Campaign generously supported this work with a
project grant (P0540).
No benefits in any form have been received or will be received from a com-
mercial party related directly or indirectly to the subject of this article.
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